Publications by authors named "Wolfram Bodenmueller"
Article Synopsis
- As of December 31, 2023, 31 studies involving 6,081 patients found that switching between biosimilars of the same biological drug is safe and effective, with most research focusing on infliximab.
- The scope of the studies has expanded to include conditions like sarcoidosis, in addition to previously studied diseases such as rheumatoid arthritis and inflammatory bowel disease.
- Regulatory bodies like the European Medicines Agency and the U.S. Food and Drug Administration have confirmed that such switches do not affect efficacy or safety, reinforcing that this practice is scientifically supported.
Background: Multiple switches (transitions) between biosimilars of the same reference biologic are now a reality, and they are expected to become more common in the future as more biosimilars enter the market. Switching between two biosimilars of the same reference biologic is generally driven by affordability, formulary requirements, or the relocation/travel of the patient. Evidence of whether switching between biosimilars of the same reference biologic provides similar safety and efficacy profiles is reviewed here.
View Article and Find Full Text PDF